Reduced microgliosis and astrocytosis in APPxPS1 mice after intranasal hNGFP61S/R100E treatment. by Simona Capsoni (161132)

“…The administration of hNGFP61S/R100E decreases (<b>C,F</b>) microgliosis and (<b>I</b>) astrocytosis. …”

Table_1_NOS3 Polymorphisms Can Influence the Effect of Multicomponent Training on Blood Pressure, Nitrite Concentration and Physical Fitness in Prehypertensive and Hypertensive Old... by Átila Alexandre Trapé (5870984)

“…At positions −786T > C and Glu298Asp, only the ancestral genotypes showed a decrease in diastolic BP (Δ% = −8.1, and Δ% = −6.5, respectively) and an increase on nitrite (Δ% = 19.1, and Δ% = 24.1, respectively) in the hypertensive group. …”

The effect of four Rab41 directed siRNAs on Rab41 mRNA level and Golgi ribbon organization. by Shijie Liu (442365)

“…Total RNA was isolated and transcribed to cDNA. Real-time PCR showed that, in cells treated by siRab41(1), siRab41(2) or siRab41(3), Rab41 transcript level was decreased ~40-50% relative to GADPH (as control), while in cells treated by siRab41(4), Rab41 transcript level was decreased >60%. …”

Effect of <i>LipB</i> Disruption on Lipoic Acid Levels and PDH-E2 Lipoylation by Svenja Günther (37469)

“…The bands correspond to PDH-E2 (75 kDa), BCDH-E2 (50 kDa), and KGDH-E2 (47 kDa). PDH-E2 lipoylation is greatly reduced in the mutant lines in comparison with wild-type, showing that the decrease in LA levels is primarily due to loss of the cofactor from the apicoplast PDH-E2-subunit. …”

Evaluation of PNA effect on CD5 expression. by Elena Cesaro (11424301)

Factor analysis of abnormal postural change cardiovascular autonomic indices within pSS patients by Fin ZJ Cai (51289)

“…RR intervals, low frequency RR power (HRV), proportion of successive RR intervals differing by more than 50 ms (pNN50), change in systolic blood pressure on standing (ΔSBP), low frequency systolic blood pressure power (BPV) and the 30/15 ratio were all decreased in patients who have primary Sjögren's syndrome (pSS) relative to control individuals on standing. …”

Platelet thrombus formation on VWF surface in the presence of Hb. by Gowtham K. Annarapu (2622811)

“…The Hb increased the thrombus area in a concentration-dependent manner under 25 dyne/cm², ***<i>P</i> < 0.0001, the size of thrombus was further abrogated by peptide AA1-50 (5 μM), ***<i>P</i> < 0.0001, but not by the control peptide. …”

Neutrophil motility in healthy donors. by Kathryn L. Butler (244702)

“…Samples were rearranged in decreasing order of the average motilities. Bars represent standard error of the mean. …”

XAV939 has no effect on growth of cancer cells in optimal growth conditions. by Renyue Bao (121721)

“…<p>Growth inhibition was determined in human breast cancer cells MDA-MB-231 (<b>A</b>) and in human colon cancer cells DLD-1 (<b>B</b>) and SW480 (<b>C</b>) following treatment with XAV939 or 21H7 for 72 h. …”

EGR1 prevents osteosarcoma cell migration into blood vessel in vivo. by Yukihiro Matsunoshita (232591)

“…To examine tumour cell invasion of blood vessels, we counted GFP- positive- 143B cells within 50 µl blood aspirates from hearts at 5 weeks after inoculation (A). …”

Collective behavior in experimental data for validating model. by Giovanna De Palo (476510)

Highly Flexible PEDOT Film Assembled with Solution-Processed Nanowires for High-Rate and Long-Life Solid-State Supercapacitors by Xiying Han (1422010)

“…Our results show that the conductivity of the films (50.8–100 S cm^–1) relies on the polymerization time of the nanowires and longer time favors doping of dodecyl sulfate anions but results in a decrease of carrier mobility from 16.08 to 6.05 cm² V^–1 s^–1. …”

OSM activates ERK-1/2, SAPK/JNK-1/2 MAP kinases, the PI3-kinase Akt and STAT1/3 in HCT116 cells and STAT3 activation is dependent of the LIFR. by Florian Beigel (174724)

“…<p>(A) Stimulation with OSM (100 ng/mL) resulted in increased phosphorylation of ERK-1/2, SAPK/JNK-1/2 kinases and induced PI3 kinase-dependent Akt phosphorylation. …”

NPB304 inhibited the MAPK pathway in MCF-7/paclitaxel cells. by Mei Mei (610571)

“…MCF-7 cells were pretreated with paclitaxel and 200 nM TPA for 24 h and subsequently exposed to paclitaxel for 48 h. (C) The expression of p-ERK1/2 was decreased in a concentration-dependent manner when MCF-7/paclitaxel cells were treated with 10 to 50 µM U0126 for 24 h. …”

Interrogation of neural network properties with optogenetics. by Chunxiao Hu (414540)

Metabolomics raw data and table of extracted peak areas for BT478, BT530 and NHA cells cultured in the presence of MPA, Compound 3 (IC80) or vehicle control, for 6 hours. by Agata Monika Kieliszek (14650298)

“…The linear gradient employed was as follows: 0–2.5 min 99% A, 2.5–7.5 min decrease to 80% A, 7.5–13 min to 55% B 652 and finally 13–15 min to 99% B and held for 1 min. …”

Supplementary Material for: Anatomical, functional, and prognostic results of vitrectomy in epiretinal membranes secondary to retinal vein occlusions by Chung Y.-R. (20312844)

“…Anatomically, the mean preoperative CMT was 501 ± 168 μm, decreasing to 348 ± 108 μm at month 24 (p=0.008). …”

Determinants of study power. by Leticia M. Nogueira (501430)

“…<p><b>A</b>. Study power decreases with increasing sample storage time (▪0 years, ▴ 5 years, •10 years). …”

Ntf3 expression levels influence gap detection thresholds in broadband background noise. by Lingchao Ji (14589524)

“…In contrast, in the GAP trials, a silent gap in the background noise of variable length (0–50 ms) was presented ending 50 ms before the startle stimulus (S). …”

Data Sheet 1_Treatment with pemafibrate ameliorates fatty liver index and atherogenic lipid profiles in Japanese patients with type 2 diabetes mellitus.pdf by Toru Suzuki (512729)

“…There was no significant change in hemoglobin A1c level over time. FLI (mean ± standard deviation: 68.1 ± 21.9 vs. 39.6 ± 25.0, P < 0.001), but not FIB-4 index as a marker of hepatic fibrosis (median [interquartile range]: 1.04 [0.78-1.39] vs. 1.01 [0.68-1.36], P = 0.909), was significantly decreased by treatment with pemafibrate for 12M, and the proportion of patients with metabolic dysfunction-associated SLD (MASLD) was significantly decreased from 92.3% (baseline) to 61.5% (12M).…”